Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - exemestanum - compresse rivestite con film - exemestanum 25 mg, mannitolum, cellulosum microcristallinum, crospovidonum typ a, carboxymethylamylum natricum a corresp. natrium 0.29 - 0.44 mg, hypromellosum, polysorbatum 80, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171, pro compresso obducto. - 2nd e 3rd line terapia avanzata di mamma-ca nelle pazienti in postmenopausa - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - exemestanum - compresse rivestite con film - exemestanum 25 mg, mannitolum, hypromellosum, crospovidonum, polysorbatum 80, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, silica colloidalis anhydrica, Überzug: carmellosum natricum, maltodextrinum, glucosum monohydricum 0.441 mg, acidum stearicum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 0.15 - 0.25 mg. - 2nd e 3rd line terapia avanzata di mamma-ca nelle pazienti in postmenopausa - synthetika

Sviss - ítalska - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - exemestanum - compresse rivestite con film - exemestanum 25 mg, mannitolum, crospovidonum, carboxymethylamylum natricum a corresp. natrium 0.1 mg, hypromellosum, polysorbatum 80, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171 pro compresso obducto. - 2nd e 3rd line terapia avanzata di mamma-ca nelle pazienti in postmenopausa - synthetika

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

sandoz spa - paroxetina cloridrato - compresse rivestite - "20 mg compresse rivestite con film" 28 compresse in blister al/pvc

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - rifampicina - rifampicina

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - rifampicina, associazioni - rifampicina, associazioni

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - rifampicina, pirazinamide e isoniazide - rifampicina, pirazinamide e isoniazide

Evrópusambandið - ítalska - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplasie al seno - agenti antineoplastici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

baxter s.p.a. - ifosfamide - ifosfamide

Ítalía - ítalska - AIFA (Agenzia Italiana del Farmaco)

novartis farma s.p.a. - letrozolo - letrozolo